Public Health Emergency - Leading a Nation Prepared
Author: Christopher Houchens, Ph.D., Director, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services
Marian Nakada, Ph.D., Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC, Inc.
Published Date: 3/17/2021 1:24:00 PM
Category: Innovations; Response & Recovery;
Launching an innovative product or technology takes more than a good idea, and there are many actions startups can take to strengthen their offering and overall chance of success as they develop the latest innovations to bolster health security, including battling COVID-19. Over the last year, the global scientific community has proven critical to our collective ability to combat the pandemic, and Blue Knight™ offers a new way to build the kinds of partnerships needed to advance potentially life-saving technology during public health emergencies.
Blue Knight is a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA) that aims to forge a path to a more prepared and protected future by providing support for strategically aligned start-up companies and elevating important topics through expert programming.
At the close of 2020, we joined the culminating session of the
BLUE KNIGHTSymposium to discuss strategies for investing in and nurturing early-stage innovation to improve health security. At the Symposium, we witnessed first-hand that when worldwide experts come together, we are able to probe deeper to address challenges and identify priorities to strengthen preparedness and health security.
We were joined by internationally recognized innovation leader, Geoffrey Ling, M.D., Ph.D., for a forthright dialogue that provided early-stage innovators with tips for overcoming barriers. The panel was led by entrepreneur Stephanie Culler, Ph.D., Co-Founder and CEO of Persephone Biosciences, a
Blue Knight company. Here are key takeaways from the discussion.
To fuel early-stage, high-risk innovations, we look for ideas with the potential to cross the ultimate finish line: meeting the unmet needs of patients. By offering transparent advice, we hope to help those on the frontlines of innovation develop stronger proposals, foster connections, and access the support needed to make their next big move.
If you are interested in taking a deeper dive into any or all of these concepts, check out the full remarks in our
At the end of the day, even with the right science, the right target market, and the right funding, the path to bringing an idea to market is prone to detours and roadblocks. Success requires creativity and unwavering passion. We believe that entrepreneurs who build a network of diverse stakeholders – all passionate about their success and who will be there to help pivot and persevere – may have a stronger chance at getting their solutions to patients.
By finding partners and mentors in the early stages, entrepreneurs can gain the expertise and insights to look ahead to anticipate and mitigate risks.
If you’re working on the frontlines of innovation with the aim to improve health security, we want to hear from you. Our
Blue Knight collaboration was formed with a keen interest in sourcing innovation that has applications for today, while improving our readiness to combat unknown threats of tomorrow. United, we are able to provide promising startups with the robust, multi-specialty mentorship and resources from both the Johnson & Johnson Family of Companies and BARDA networks.
It’s never too early to start making connections and building the foundation and support that may help propel your science or technology forward. If you’re ready to progress your compelling idea for improving preparedness and response to health threats, visit the
Blue Knight website to get connected or apply to join.
Disclaimer: The content covered in this blog is intended for educational and informational purposes only and may contain opinions by persons and organizations not affiliated with Johnson & Johnson Innovation LLC, and/or its parent or affiliated companies (hereinafter collectively referred to as “JJI”). JJI makes no representations, warranties, express or implied, as to the content, the views, advice, or the information presented. This content is not intended to influence the use, sale, recommendation, or promotion of any products or services of JJI, Johnson & Johnson or its affiliates.
Source: Johnson and Johnson Innovation - JLABS
This is a moderated blog-we will review all comments before posting them. To learn more, please see ASPR Blog and Social Media Comments.
Please validate the following expression by entering the correct numeric value.
Question: What is one + seven ? Answer:
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages